Marcos Berry, MD1, Lionel Urrutia, MD1, Patricio Lamoza2, Alfredo Molina1, Rodolfo Lahsen1, Shirley Marquina1. 1Clinica Las Condes, 2Hospital de Maipu
Introduction: Morbidly obese patients with T2DM who undergo bariatric surgery have improvement or remission of their diabetes. We report our results in terms of type 2 diabetes(T2DM) control in obese patients after laparoscopic sleeve gastrectomy(LSG), analyzing the excess weight loss (EWL%), metabolic performance after surgery, and morbi-mortality.
Aim: Evaluate the results of metabolic control in the treatment of obese patients with T2DM undergoing LSG.
Methods: A prospective case series of obese, well-controlled T2DM patients underwent LSG consecutively between April 2006 and December 2013.
Results: 95 patients (5.92%) from a universe of 1605 subjected to LSG, 56 male and 39 female, mean age 49.48 years(24-70), were operated upon and underwent follow-up for a mean of 36 months (3 – 85). Mean preoperative BMI versus follow-up BMI were 36.43(30.2-51) and 26.2(24-28), respectively, and the mean EWL% was 77.57 %. Mean preoperative fasting glucose levels and HbA1C decreased from 144,53 mg%(84-250) to 95.1mg%(70-120) and from 7 %(5.2-11.6) to 5.79%(5.3-6.9), respectively. At follow-up, 89% of patients did not require further oral treatment for diabetes, while 11% witnessed a significant decrease in dosage of medication and/or were being progressively tapered off of medication.
Comorbidities: hemoperitoneum 1.05% and perigastric hematoma 1.05%; no mortality.
Discussion: LSG is a safe and an effective surgery for mild and well controlled T2DM patients, achieving a very good metabolic control. Further follow-up is necessary to evaluate long term results and may provide valuable information in optimizing patient selection for this procedure.
Keywords: Bariatric surgery, Morbid obesity, Sleeve gastrectomy, Remission, Type two diabetes.